Last reviewed · How we verify

NCT04441021

Feasibility Assessment of Risk Stratification and Oral Challenge in Hospitalized Children at Low Risk for Antibiotic Allergy

Completed Last updated 30 June 2021
What this trial tests

trial testing Penicillin Allergy Risk Stratification and Evaluation in Penicillin Allergy in 20 participants. Completed in 29 June 2021.

Timeline
15 September 2020
Primary endpoint
1 December 2020
29 June 2021

Quick facts

Lead sponsorVanderbilt University Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment20
Start date15 September 2020
Primary completion1 December 2020
Estimated completion29 June 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Vanderbilt University Medical Center

Who can join

0 and older, any sex, with Penicillin Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Children are often reported to have antibiotics allergies, with approximately 10% of the US population labeled as allergic to an antibiotic. Recent studies have demonstrated that a large majority of children with a penicillin allergy label do not have a true IgE-mediated allergy. Appropriately delabeling antibiotic allergies has been shown to improve patient care outcomes and lower health care costs. However, efforts to implement these assessments in practice are lacking, particularly in the hospital setting. Therefore, there is a need for hospital-based risk assessment and delabeling strategies for hospitalized children. The investigator's objective is to determine the feasibility of implementing a hospital-based approach to penicillin allergy risk stratification and evaluation of patients at low-risk for true allergy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Feasibility of a Centralized, Pharmacy-Led Penicillin Allergy Delabeling Program.
    Antoon JW, Grijalva CG, Grisso AG, Stone CA, et al · · 2022 · cited 14× · PMID 35678128 · DOI 10.1542/hpeds.2021-006369
  2. Breaking the Mold: Safely Delabeling Penicillin Allergies in Hospitalized Children.
    Antoon JW, Grisso AG, Stone CA. · · 2021 · cited 3× · PMID 33849961 · DOI 10.1542/hpeds.2020-005280

Verify or expand the search:

Other recruiting trials for Penicillin Allergy

Currently open trials in the same condition.

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing